Influence of CYP2D6 polymorphisms on symptomatology and side effects of patients with schizophrenia in Malaysia
- Author:
Zalina Zahari
;
Mohd Razali Salleh
;
Lay Kek Teh
;
Rusli Ismail
- Publication Type:Journal Article
- Keywords:
Cytochrome P450 CYP2D6, schizophrenia, treatment outcomes, neurosciences
- From:Malaysian Journal of Medical Sciences
2009;16(3):13-22
- CountryMalaysia
- Language:English
-
Abstract:
Background: Our objective was to investigate the association of CYP2D6 polymorphisms with
symptoms and side-effects of patients with schizophrenia.
Methods: The subjects were 156 patients with schizophrenia undergoing antipsychotic treatment
at a psychiatric clinic. Patients with co-morbid diagnoses of substance abuse or mental retardation were
excluded from the study. Psychopathology was evaluated using the Positive and Negative Symptoms
Scale (PANSS). Extrapyramidal side-effects and akathisia were assessed with the Simpson Angus Scale
(SAS) and the Barnes Akathisia Rating Scale (BARS), respectively. DNA was extracted from blood and
subjected to PCR-genotyping.
Results: We found that CYP2D6 polymorphisms were significantly associated with a subtotal
negative PANSS score. In addition, CYP2D6 is not related to side-effects of antipsychotic therapy, or
SAS and BARS scores. The results suggest that CYP2D6 polymorphisms may have implications in
treatment response.
Conclusions: Therefore, CYP2D6 may be a predictor for treatment outcomes of patients with
schizophrenia. However, further investigation is required to confirm these findings in a larger sample.
- Full text:W020151021609515750404.pdf
